![vial labelled 'COVID-19 SARS-CoV-2 VACCINE' next to syringe blood samples in tube and stethoscope](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/COVID-19-VACCINE_2-375x250.jpg)
Bayer has agreed to support the further development, supply and key territory operations of the CVnCoV COVID-19 vaccine candidate by signing a collaboration and services agreement with CureVac.
According to the enterprises, Bayer will facilitate this by contributing its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain performance and support in selected countries.
"The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate," said
"We are very happy to join forces with Bayer, whose expertise and infrastructure will help us make our vaccine candidate CVnCoV even more rapidly available to as many people as possible," said Dr
Based on the collaboration agreement, CureVac will be the Marketing Authorization holder for the product, while Bayer will support CureVac with country operations within the
CVnCoV is currently being investigated in a global Phase IIb/III trial.
The post Bayer to support development and supply of CVnCoV COVID-19 vaccine appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2021. All Rights Reserved., source